Vial sizes vary by vendor. Smaller bottles are usually 3 mL; larger bottles are often 10 mL. Match the label on the vial you actually bought, then use the calculator below if you need to adjust.
Overview
Retatrutide is a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, making it one of the most potent metabolic peptides available.
PubMed evidence
-
PMID 37366315 (2023) — Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Human trial evidence; supports clinical context without changing the protocol.
-
PMID 37385280 (2023) — Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Human trial evidence; supports clinical context without changing the protocol.
-
PMID 40563436 (2025) — Retatrutide-A Game Changer in Obesity Pharmacotherapy. Review evidence; use as context, not primary protocol input.
Preparation
Recon: 10 mg vial + 2 mL BAC (5 mg/mL).
Protocol
| Period | Dose | Units (@ 5mg/mL) | Frequency |
|---|---|---|---|
| Weeks 1-4 | 2.5 mg | 50 u | 1x/week |
| Weeks 5-8 | 5 mg | 100 u | 1x/week |
| Weeks 9-12 | 7.5 mg | 150 u | 1x/week |
| Weeks 13-16 | 10 mg | 200 u | 1x/week |
| Weeks 17-20 | 12.5 mg | 250 u | 1x/week |
| Weeks 21-24 | 15 mg | 300 u | 1x/week |
Cycle
12 weeks on, 4 weeks off. Half-life is approximately 6 days.
Research coverage
Related reporting from Compound Chronicle, which tracks the peer-reviewed literature on Retatrutide Protocol.
- How Structural Design Defines Next-Generation GLP-1 Analogs Sep 15, 2026
A structural overview of how DPP-4 resistance, lipidation, signaling bias, and multi-receptor agonism produce progressively more sophisticated incretin therapies.
- GLP-1 Agonists for MASH Fibrosis: an Overview Sep 8, 2026
A Cell Reports Medicine review surveys incretin-based therapies for MASH fibrosis — from FDA-approved semaglutide to emerging dual and triple GLP-1 agonists.
- Retatrutide Lowers BP and Lipids: A Meta-Analysis Sep 7, 2026
The first meta-analysis of retatrutide's BP and lipid effects across RCTs finds significant reductions in SBP, DBP, total cholesterol, and triglycerides.
- Online-Sourced Retatrutide and DKA Risk: A Case Report Sep 1, 2026
A Cureus case report describes impending DKA after online-purchased retatrutide use in type 1 diabetes — a real-world warning about unregulated research peptides.
- Retatrutide and Cardiovascular Risk Biomarkers Aug 22, 2026
A new analysis in Diabetes, Obesity & Metabolism reports biomarker improvements across cardiac-related measures in adults with obesity, with or without type 2 diabetes.